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Summary Among 114 breast cancers in Taiwan, the prevalence of p53 mutation (22.8%) and p53 accumulation (38.3%) was similar to that
in high-incidence areas. However, novel patterns of p53 abnormalities, including unique sites or types of mutation (i.e. an excessive
proportion of G:C to A:T transition at CpG site), and accumulation of wild-type p53 either within nuclear or cytoplasmic compartments were
noted. These may have relevance to breast cancer in Taiwan, a low-incidence area.
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Taiwan is considered a low-incidence area for breast cancer. The
cause of this lower risk is potentially of great importance. Our
epidemiological study to explore risk factors suggests that breast
cancer in Taiwan is reproductive hormone dependent (Yang et al,
1997), as itis inhigh/moderate-risk areas.The hypotheses involving
reproductive hormones in carcinogenesis are based on the general
concept that cell division plays a crucial role in the pathogenesis of
cancer, and thatreproductive factors that increase mitotic activity in
breast epithelium also increase risk (Pike et al, 1993). On this basis,
the role of reproductive hormones during tumorigenesis is largely
related to an epigenetic alteration and tumour promotion. On the
other hand, the mechanisms contributing to direct DNA damages,
genetic alteration and tumour initiation in breast cancer still remain
uncertain.
In breast cancer, more than 300 mutations in the p53 gene have
been documented, accounting for about 25% of all breast cancers
tested (Greenblatt et al, 1994), but largely in high-risk areas such
as Europe and the United States. We have, therefore, studied p53
abnormalities in Taiwan, the first such study, to our knowledge, in
a Chinese or Taiwanese population.
MATERIALS AND METHODS
Malignant tissue was collected from 114 Taiwanese patients
undergoing mastectomy or wide local excision for breast cancer
during a period from October 1994 to September 1995. The partic-
ipants were all newly diagnosed patients with primary diagnoses
and pathological confirmation of breast cancer. All tumour speci-
mens were screened for mutations in exons 5-8 of the p53 gene,
and p53 protein accumulation (overexpression) was detected by
immunohistochemistry (IHC).
DNA was extracted from breast tumour specimens as previ-
ously described (Shen et al, 1993). The mutation analysis ofexons
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5-8 of p53 was firstly screened by polymerase chain reaction
and single-stranded conformation polymorphism analysis (PCR-
SSCP) (Orita et al, 1989). All mutants, i.e. DNA fragments
showing mobility shifts byPCR-SSCP, werereamplified,and were
further identified for the sites of mutation by direct DNA
sequencing. DNA was sequenced with a sequencing kit (Sequenase
PCR Product, United States Biochemical). The primer sets and
conditions for these reactions are shown in Table 1. In this study,
all mutations identified were subjected to reamplification and rese-
quencing of the p53 segments using different primers (Table 1),
and further confirmed by sequencing complementary strands, thus
eliminating the possibility ofcreating artefacts by PCR.
Sections (5 gm thick) from fixed, paraffin-embedded tumours
from 77 patients were interacted with three different anti-p53
monoclonal antibodies for accumulation (overexpression) of p53.
Two antibodies, Ab2 (Oncogene Sciences Manhasset, NY, USA)
and Anti-p53 (Sigma, St Louis, MO, USA) recognize epitopes on
both wild-type p53 and mutant p53, and one, Ab3 (Oncogene
Sciences, specifically recognizes mutant p53. Bound antibody was
further interacted with a secondary antibody, and the signal was
detected with an avidin-biotin complex system and diaminobenzi-
dine kit (Vector Laboratories, Burlingame, CA, USA). Diamino-
benzidine yielded a reddish brown stain if positive. The presence
of 'positive staining' of wild-type/mutant p53 or mutant p53 was
assessed microscopically to demonstrate tumours with 50% or
more cells expressing signal. Positive staining was further exam-
ined to locate the sites (i.e. nucleus or cytoplasm) of the signal.
Thirty-seven cases were not detected for p53 accumulation
because ofinsufficient amounts oftumour tissue for IHC.
RESULTS
Twenty-six mutations (22.8%) were found in exons 5-8 and adja-
cent intronic regions among the 114 breast cancer specimens
studied. SSCP and sequence change of representative mutations
are shown in Figures 1-3. The precise codon alterations are listed
in Table 2. Missense mutation was the most common type ofpoint
mutations (17/26, 65.4% of mutation), and codons 175, 179, 237,
248 and 273 were found to mutate in two cases of breast cancer
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Table 1 Primer pairs and corresponding annealing temperature used in PCR-SSCP and DNA sequencing for different exons in p53a
Exon Name Location Position Sequence Annealing temp.
PCR-SSCP
5 5c Intron4 13003-26 5'-TCTGTTCACTTGTGCCCTGACTTT-3' 63
5d Intron5 13260-84 5'-ACCCTGGGCAACCAGCCCTGTCGTC-3'
6 6c Intron5 13265-88 5'-CAGGGCTGGTTGCCCAGGGTCCCC-3' 63
6d Intron6 13461-85 5'-ACTGACAACCACCCTTAACCCCTCC-3'
7 7c Intron6/exon7 13993-4014 5'-CTCCTAGGTTGGCTCTGACTGT-3' 63
7d Intron7 14135-59 5'-GAGGCTGGGGCACAGCAGGCCAGTG-3'
8 8c Intron7 14400-24 5'-TAGGACCTGATTTCCTTACTGCCTC-3' 58
8d Intron8 14611-35 5'-AACTGCACCCTTGGTCTCCTCCACC-3'
PCR for DNA sequencing
5-6 5c Intron4 13003-26 5'-TCTGTTCACTTGTGCCCTGACTTT-3' 58
6d Intron6 13461-85 5'-ACTGACAACCACCCTTAACCCCTCC-3'
7-9 7a Intron6/exon7 13986-4002 5'-GTGTTATCTCCTAGGTT-3' 58
9b Exon9/intron9 14749-65 5'-AGACTTAGTACCTGAAG-3'
Sequencing primers
5 5c Intron4 13003-26 5'-TCTGTTCACTTGTGCCCTGACTTT-3'
5a Intron4/exon5 13040-59 5'-TTCCTCTTCCTACAGTACTC-3'
5d Intron5 13260-84 5'-ACCCTGGGCAACCAGCCCTGTCGTC-3'
6 6e Intron5 13241-60 5'-GAGCAGCTGGGGCTGGAGAG-3'
6c Intron5 13265-88 5'-CAGGGCTGGTTGCCCAGGGTCCCC-3'
6d Intron6 13461-85 5'-ACTGACAACCACCCTTAACCCCTCC-3'
7 7a Intron6/exon7 13986-4002 5'-GTGTTATCTCCTAGGTT-3'
7g Intron7 14135-59 5'-GAGGCTGGGGCACAGCAGGCCAGTG-3'
7f Intron7 14161-81 5'-GCCCAGGGGTCAGCGGCAAGC-3'
8 8e Intron7 14355-80 5'-GGGTGGTTGGGAGTAGATGGAGCCTG-3'
8c Intron7 14400-24 5'-TAGGACCTGATTTCCTTACTGCCTC-3'
8d Intron8 14611-35 5'-AACTGCACCCTTGGTCTCCTCCACC-3'
aNucleotide positions shown in the table are based on the postions used in the Genbank DNA Library.
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Figure 2 A missense mutation was identified in codon 175 (case 060)
Figure 1 Band shift in SSCP (single-stranded conformation polymorphism
analysis) and further confirmation by DNA sequencing showing a nonsense
mutation in codon 167 (case 050)
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Table 2 p53 mutation and accumulation profiles in 114 breast cancers in Taiwan
Antibody against
Wild-type/mutanta Mutant
Case Exon Codon Codon change Amino acid change Type Nucleus Cytoplasm Nucleus Cytoplasm
26 cases with mutation
005 7 237 ATG -*ATT Met- lle Missense + - +
024 7 249 AGG -+TGG Arg -Trp Missense + - +
038 8 282 CGG - TGG Arg - Trp Missense + - +
043 7 237 ATG - ATA Met lie Missense + - +
065 5 163 TAC-TGC Try* Cys Missense + - +
068 8 272 GTG -TTG Val -Leu Missense + - +
115 5 179 CATe CGT His - Arg Missense + - +
163 8 273 CGT-CAT Arg -His Missense + - +
009 7 234 TAC -TGC Tyr Cys Missense + + + +
077 7 248 CGG -TGG Arg -Trp Missense + + +
089 5 179 CAT+CCT His -Pro Missense + + +
069 8 281 GACO CAC Asp His Missense + + - +
132 8 273 CGTOCAT Arg - His Missense +
060 5 175 CGCOCAC Arg -His Missense + - - ND
092 7 248 CGG G CAG Arg - Gln Missense ND ND ND ND
104 5 175 CGC - CAC Arg - His Missense ND ND ND ND
131 5 141 TGC-* TAC Cys - Tyr Missense ND ND ND ND
063 Intron 8 +24 G -+ A Intronic +
167 Intron 4 -1 G-A Intronic + - +
100 Intron 7 +1 G-A Intronic
050 5 167 CAG -+TAG Gln - Stop Nonsense
012 8 288 AAT C -+ ATC Asn -4 Deletion/frameshit - - - -
097 8 305 MG -*AAAG Lys -+ Insertion/frameshift - - - -
037 5 141 8 bases deletion Frameshift - - -
111 6 214 CATo CAC His -His Silent - - -
064 8 283 CGC C OGG Arg - Arg Silent - + -
54 cases with wild-type p53 hadIH@,
1 (1.9%) case + + +
2 (3.7%) cases + + - +
6 (11.1%) cases + +
5 (9.3%) cases +
2 (3.7%) cases - +
38 (70.4%) cases
34 cases with wild-type p53 didnothave IHC
aAccumulation of the wild-type/mutant form of p53 was detected by two monoclonal antibodies. The positive results were defined by consistently displaying
positive signals using both antibodies. The results obtained by both antibodies demonstrated a very high degree of consistency, and only two cases yielded
conflicting results. blmmunohistochemistry. ND, Not done.
specimens, whichrepresentedapproximately 60% ofthe missense
mutants. Further review of the database containing more than 300
p53 mutations in breast cancer (Cariello et al, 1994) showed that
the pattern of change of codon/amino acid in three of our cases
(cases 024,068 and089) have never been reported. We also iden-
tified three cases with frame-shift mutation due to deletion or
insertion, and the sites ofmutation in two ofthem,i.e. cases 12 and
97, have not been previously reported. Analysis ofthe prevalence
and spectra of p53 mutations shows that nucleotide transition,
including G:C -* A:T(at eitherCpG ornonCpG sites) and A:T -*
G:C, is themajorpatternfound(Table 3),constituting 65% oftotal
p53 mutations identified.
This study found theproportion ofpositive IHC (which indicates
the presence of either wild-type or mutant p53 accumulation) to
be 100% (14/14), 0% (0/4) and 29.7% (16/54) in the missense
mutant cases, nonsense/frame-shift mutant cases and wild-type
cases (including two cases with silent mutation) respectively
(Table 2). These figures result in an estimation increase in p53
protein accumulation of 38.3% (100% x 16/114 + 0% x 5/114 +
29.7% x 93/114) in 114 breast cancer patients. We also used anti-
body specific for the mutant p53 form, and we further examined
the site (i.e. nucleus or cytoplasm) of positive IHC in individual
tumour cells (Figures 4 and 5). In 14 cases with p53 missense
mutation, the common pattern (eight cases) exhibited a phenotype
of positive nuclear staining detected by antibodies against both
wild-type/mutant forms and mutant form p53 but with negative
cytoplasmic staining detected by either antibody (Table 2). Four
cases with nonsense/frameshift mutations showed negative
staining in any location detected by antibodies against wild-
type/mutant and mutantp53. Two cases harbouring silent mutation
were confirmed by negative staining of mutant p53, but wild-type
p53 was found in case 064. On the other hand, in 54 cases with
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Case 097 (T) -GGG-AGC-ACT-AAA-GCG-AG-gtaagoaagc
Lys Ala
Figure 3 A frame-shift mutation due to an insertion of adenine at codon 175
(case 097)
undetectable p53 mutation in exons 5-8, negative staining was
expected in most of them (38/54), nevertheless p53 accumulation
could be detected in 16 cases (Table 2). On the basis ofIHC detec-
tion by antibody specific to mutant p53, we classified these 16
cases into two groups: those with positive mutantp53 (three cases),
suggesting the presence of mutation, and those without mutant
p53 (13 cases), suggesting the accumulation of wild-type p53. In
13 cases without mutant p53, 11 cases showed positive nuclear
staining and eight cases displayed cytoplasmic p53 accumulation.
DISCUSSION
Proportions of p53 mutation (22.8%) and of p53 accumulation
(38.3%) comparable with those inhighincidence areas were found
in 114 Taiwanese breast cancers. However, novel pattems of p53
Figure 4 Sequential dissection of a case of ductal carcinoma in situ. (A) A
standard haematoxylin- and eosin-stained section (40x). (B) Positive (brown)
staining using antibody against mutant p53 (40x). (C) p53 localized mostly to
cytoplasm (400x). (D), negative control (400x)
abnormalities, including unique sites or types of mutation, and
overexpression ofp53 protein, were detected in this study.
Current evidence of the structure-function relationship of p53
(Cho etal, 1994) suggests that some mutants ofp53 altertheirfunc-
tion and confer upon cells a growth advantage. Previous reviews
have noted that major mutational hotspots in breast cancer occur in
three amino acids (175, 248 and 273) in p53 (Greenblatt et al,
1994), the codons of which are all known to be related to specific
functions ofp53. The affected codons found in this study involved
amino acids related to the role of p53 as a transcription factor
binding specific DNA sequences (e.g. codon 248 in cases 077 and
092, codon 273 in cases 132 and 163) or to bind Zn2+ (e.g. codon
179 in cases 089 and 115), andrelated tomaintaining wild-type p53
conformation (e.g. codon 175 in cases 060 and 104, codon 249 in
case 24). Subsequently, genomic alterations in these amino acids
may result in a failure to transcribe cell-cycle regulatory proteins
Table 3 Spectra of p53 mutation in exons 5-8 in breast cancer in Taiwan and other populationsa
Transitions Transversions
Percentage of Deletion/ G:C-A:T G:C-*A:T at A:T-G:C G:C-4C:G G:C-T:A A:T->C:G A:T-T:A
mutation (no. insertion at CpG non-CpG
of tumours tested)
Taiwanese
22.8 (26) 11.5 (3) 30.8 (8) 19.2 (5) 15.4 (4) 7.7 (2) 7.7 (2) 3.9 (1) 3.9 (1)
Current p53 mutation found
22.0 (338) 16 23 13 11 8 13 6 7
Caucasian in Europe
22.9 (122) 11.5 23.7 18.2 8.8 7.4 18.2 8.1 4.1
Caucasian in the United States
23.7 (60) 11.0 19.2 23.3 23.3 11.0 5.5 4.1 2.7
Japanese
20.1 (63) 17.1 23.4 17.0 19.2 4.3 2.1 6.4 10.6
aThe results of 21 studies conducted to examine p53 mutation in breast cancer published in 1990-95 have been included in this table. Incomplete information,
e.g. mutation without confirmation by direct sequencing, is not included.
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Figure 5 Two cases of primary infiltrating ductal carcinoma stained for p53 using antibody against wild/mutant p53. (A) p53 shows largely nuclear localization.
(B) p53 is localized largely within the cytoplasm
(e.g. p21) (el-Deiry, et al, 1994), and gain of oncogenic function.
More specifically, experimental evidence indicates that at codon
175, only one of the two mutations (i.e. C:G -* T:A and G:C -*
A:T transitions) obtain selective growth advantage (Arg -* His but
not Arg -> Cys) (Greenblatt et al, 1994), which is consistent with
our finding that, in cases 060 and 104, only Arg -* His was
observed. On the otherhand, the consequence ofothermutants with
'non-hotspot' missense mutation or intronic mutation must be eval-
uated at the p53 protein level.
Compared with p53 mutation spectra in other populations
(Table 3), largely from high-incidence areas, our breast cancers
with mutant p53 were characterized by a higher proportion ofG:C
-* A:T transition at the CpG site, suggesting that different mecha-
nisms are involved in our breast cancers. Given that G:C -> A:T
mutation occurs largely at sites where cytosine is methylated (i.e.
the CpG site), experimental work and observation in humans
strongly suggest that deamination of5-methylcytosine (as opposed
to mispairing of an O6-methylguanine adduct with thymine) is the
usual mechanism by which an G:C -> A:T transition is found at a
CpG dinucleotide in human tumour (Greenblatt et al, 1994).
Spontaneous deamination ofDNA (Wink et al, 1991), endogenous
exposure to nitric oxide (Wink et al, 1991; Liu and Hotchkiss,
1995) and endogenous methylation driven by methyltransferase
and S-adenosylmethionine (Shen et al, 1992) are three possible
causes fordeamination, and are currently under examination in our
ongoing study.
The endogenous mechanism ofslipped mispairing (Ripley 1990;
Greenblatt et al, 1996) can be readily applied to explain frameshift
mutation ofsingle-base deletion and insertion in ourcases, because
the sites ofmutation were located at 2-bp DNA motifs.
The accumulation of missense p53 mutant in cells is due to
conformational changes in the mutant p53 polypeptide resulting in
increased stability, whereas wild-type p53 protein or nonsense/
frameshift p53 mutants have a short half-life and are not usually
detected by IHC. Therefore, most ofthe missense mutations, either
at hotspots or non-hotspots, showed positive nuclear IHC, and all
nonsense/frame-shift mutations show negative IHC. However, it
has to be recognized that tumorous accumulation of p53 may
reflect more the environment of the tumour cell than simply the
intrinsic structure ofthe protein (Hall and Lane, 1994). The unex-
pected differences in IHC phenotypes in cases with same types of
mutations may reflect this fact. Furthermore, an important issue
concerning heterogeneity of tumour cells has to be raised. We
found that not all staining was uniform and, even within a single
microscopic field, some cells showed intensive positive staining
whereas other cells were weakly positive or negative. This issue of
heterogeneity can also be demonstrated by three of our cases with
missense mutation (cases 69, 77 and 89), whose IHC phenotypes
showed the possibility of coexistence of accumulation of both
wild-type and mutant forms ofp53.
It is interesting to note that a significant proportion (16/54) of
our wild-type breast cancer revealed p53 protein expression in the
nucleus or cytoplasm. These cases may harbour mutations in p53
exons not included in our analysis. However, an undetectable level
of the mutant form of p53 by mutant-specific antibody indicates
the otherpossibility that mostofthese proteins were wild-type p53.
Further examination to locate this protein reveals a significant vari-
ation, and different locations may reflect different mechanisms.
Normal lactating breast tissue has been shown to accumulate p53
in the cytoplasm of ductal cells, suggesting a distinct mechanism
to inactivate p53 (Moll et al, 1992). Breast cancers that contain
the wild-type form of p53 protein may inactivate its tumour-
suppressing activity by stabilizing this protein in the nucleus or in
the cytoplasm. The presence of p53-complexing proteins, such as
MDM2 (Momand et al, 1992) or immediate-early 2 protein of
human cytomegalovirus (a breast milk-transmitted virus) (Speir et
al, 1994) in these tumours is currently under investigation.
The findings suggest that distinct mechanisms or different
carcinogens may be involved in breast cancerin this low-incidence
area. (The study ofmore cases is needed to confirm these results.
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